MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company developing artificial intelligence-driven voice analytics for drug and alcohol intoxication detection, has completed manufacturing of its next-generation Edge AI Intoxication Detection Kiosk. The milestone marks a step forward in the company's effort to commercialize a rapid, non-invasive alternative to conventional screening methods, with potential implications for safety-sensitive industries that rely on frequent impairment testing.
The new hardware builds on a prototype developed in June and is designed to support MindBio's proprietary Voice AI technology, which analyzes vocal characteristics to identify potential impairment. According to the announcement, MindBio is continuing software integration, system testing and validation of its predictive models against conventional breath alcohol and oral fluid testing methods. A potential initial commercial pilot is targeted for later this year, which would provide an opportunity to evaluate the technology's performance in a real-world environment against existing testing methods.
The kiosk is being developed as a rapid, non-invasive alternative to conventional drug and alcohol screening, targeting safety-sensitive industries including mining, aviation, construction, heavy transport and law enforcement. MindBio aims to enable more frequent, large-scale workplace screening while potentially reducing testing costs, administration time and operational disruptions. The company's AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. MindBio is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments.
The completion of manufacturing is significant because it moves the technology from prototype to a deployable product, a critical step before any commercial rollout. If the planned pilot demonstrates reliability against established testing methods, MindBio could offer employers a tool that enables more frequent screening without the logistical burden of breathalyzers or oral fluid tests. For investors, the announcement signals progress toward potential revenue generation, though the company still faces validation and regulatory hurdles. The latest news and updates relating to MBQIF are available in the company's newsroom at https://nnw.fm/MBQIF.
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other corporate communications services. Full terms of use and disclaimers are available on the NetworkNewsWire website at https://www.NetworkNewsWire.com/Disclaimer.
